A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection

Article Gastroenterology & Hepatology

Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial

Loren Laine et al.

Summary: This study found that vonoprazan, a potassium-competitive acid blocker, was noninferior and superior to the PPI lansoprazole in healing and maintenance of erosive esophagitis, particularly in patients with more severe cases.

GASTROENTEROLOGY (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure

Carmelo Scarpignato et al.

Summary: Vonoprazan, a potassium-competitive acid blocker, is being investigated for the treatment of erosive esophagitis and Helicobacter pylori infection. A population pharmacokinetic (popPK) model based on pooled data sets from Asia and Europe was developed to evaluate the impact of different covariates on vonoprazan exposure. Clinical covariates including fed/fasting status, race, sex, disease status, weight, serum creatinine, and age were identified, but their impact on vonoprazan exposure was smaller than dose adjustments. Race had limited impact on exposure, suggesting that efficacy and safety data from Asian populations are applicable to non-Asian populations.

JOURNAL OF CLINICAL PHARMACOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects

Loren Laine et al.

Summary: The study on vonoprazan and lansoprazole in US subjects showed that vonoprazan had more rapid and potent inhibition of intragastric acidity compared to lansoprazole. The research demonstrated that vonoprazan was more effective in maintaining a higher proportion of 24-hour periods with intragastric pH > 4 on days 1 and 7, when compared to lansoprazole.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

The Effect of Food on the Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan

Darcy J. Mulford et al.

Summary: The study found that food did not have a significant impact on vonoprazan exposure, indicating that vonoprazan can be administered without regard to food intake. Adverse events were mild and unrelated to the study drug in the subjects.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2022)

添加到收藏夹

Article Immunology

Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function

Mijeong Son et al.

Summary: Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder. The use of proton pump inhibitors (PPIs) may worsen IBD. However, tegoprazan can improve IBD and enhance intestinal epithelial barrier function without causing gut dysbiosis.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial

William D. Chey et al.

Summary: This study evaluated the efficacy of vonoprazan, a potassium-competitive acid blocker, in H pylori eradication and found that it was superior to the standard triple therapy, especially in the clarithromycin-resistant strains.

GASTROENTEROLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

The appropriate cutoff gastric pH value forHelicobacter pylorieradication with bismuth-based quadruple therapy

Haoran Ke et al.

Summary: Double dose esomeprazole is associated with better intragastric acid suppression. A median 24-h intragastric pH of 5.7 could be an appropriate cutoff value for predicting the successful eradication of H. pylori. Bismuth-based quadruple therapy resulted in high H. pylori eradication rates in both PPI standard or double doses.

HELICOBACTER (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Vonoprazan shows efficacy similar to that of proton pump inhibitors with respect to symptomatic, endoscopic, and histological responses in patients with eosinophilic esophagitis

Takuya Kuzumoto et al.

Summary: In patients with eosinophilic esophagitis (EoE), potassium-competitive acid blockers (P-CABs) have shown similar efficacy to proton pump inhibitors (PPIs). There were no significant differences in the rates of complete relief in clinical symptoms, endoscopic complete remission, and histological complete remission among the therapy groups.

ESOPHAGUS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis

Theodore Rokkas et al.

Summary: The study compared the effectiveness of different first-line regimens for Helicobacter pylori infection through a network meta-analysis. Results showed that vonoprazan triple therapy and reverse hybrid therapy achieved high eradication rates above 90%, with levofloxacin triple therapy performing best in Western countries. Standard triple therapy was found to be the least efficacious in this analysis.

GASTROENTEROLOGY (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review

Shailja C. Shah et al.

Summary: The purpose of this CPU Expert Review is to provide clinicians with guidance on the management of Helicobacter pylori after initial eradication therapy failure. The review is not formal systematic, but based on literature to provide practical advice. The strength or quality of the evidence was not formally rated, instead a combination of available evidence and consensus-based expert opinion were used to develop best practice advice.

GASTROENTEROLOGY (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Review article: potassium-competitive acid blockers for the treatment of acid-related disorders

Yousef Abdel-Aziz et al.

Summary: Potassium-competitive acid blockers (P-CABs) have shown potential advantages over proton pump inhibitors (PPIs) in managing acid-related disorders, with most clinical trials conducted in Asia. Some P-CABs, like vonoprazan, are currently licensed in Asian and South American countries, with developments underway for North America.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology